Innovative/Translational Cancer Research Grants

Funding Agency:
Mary Kay Foundation

The Mary Kay Foundation℠, a funding source for cancer research, is currently accepting applications for innovative grants for translational research in ovarian, uterine, breast, or cervical cancer.

The program will offer between ten to fifteen grants. The awards will be up to $100,000 each (combined direct and indirect costs). The grant period is for two years. Applications must be submitted by one Principal Investigator, selected by the Institution. Only one grant application will be accepted from each accredited medical school and schools of public health in the United States. Grants are limited to the United States.

Deadlines:

  • Duke Internal: November 26, 2018
  • Sponsor's Application Deadline: February 8, 2019

If you are interested in this funding opportunity, please submit the following information to erin.carr@duke.edu by Monday, November 26th .

1.      NIH style biosketch for the applicant

2.      2 page description of project and draft budget justification.

Agency Website

Eligibility Requirements

The Principal Investigator that completes the applications must be Asst., Assoc., or Full time professor and the same person who signs the electronic signature. Names must match exactly. Postdoctoral trainees and instructions are NOT eligible.

Amount

$100,000

Amount Description

The grant will be up to $100,000 (combined direct and indirect costs) for a two-year period.  If indirect costs are requested, they cannot exceed 15%.  If selected, the funds will be paid in two payments.  The first payment will be after receipt of the executed contract.  The second payment will be mailed following receipt of the first year status report.  The Foundation anticipates funding between ten and fifteen grants.

Funding Type

Grant

Duke Awardees

2004
Victoria Seewaldt, M.D.,
Duke University School of Medicine, associate professor, breast cancer research.
Will investigate genes involved in vitamin A processing to determine if their loss is associated with increased risk for developing breast cancer.

2003
Susan J. Littman, M.D., M.S
The Breast Cancer Susceptibility Gene, BRCA2: Isolation and Study of Its Biological Activity in DNA Repair.

Eligibility

African American
Faculty
Junior Faculty
Women

Category

Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

Internal Nomination

If you are interested in this funding opportunity, please submit the following information to erin.carr@duke.edu by Monday, November 26th .

1.      NIH style biosketch for the applicant

2.      2 page description of project and draft budget justification.

 

Internal Deadline

November 26, 2018

External Deadline

February 8, 2019